Several major grocers are taking on an Israeli pharmaceutical company, and its subsidiaries, saying the drug maker is ...

New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in ...

Neurology Live ® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased to announce the 2025 Giants of Multiple ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

The Multiple Sclerosis Treatment Optimization Program (MSTOP) was motivated by research showing that Black and Hispanic ...

Shares of Immunic (NASDAQ:IMUX) lost ~22% in the premarket on Wednesday after the immunology-focused biotech posted data from ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Researchers have identified a new biomarker in multiple sclerosis (MS): the thickness of the inflammatory rim surrounding ...

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple ...